- Home
- CANF vs INDP Comparison
CANF vs INDP Comparison
Compare CANF & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- INDP
- Stock Information
- Founded
- CANF 1994
- INDP 2000
- Country
- CANF Israel
- INDP United States
- Employees
- CANF N/A
- INDP N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- INDP Health Care
- Exchange
- CANF Nasdaq
- INDP Nasdaq
- Market Cap
- CANF 13.5M
- INDP 6.0M
- IPO Year
- CANF N/A
- INDP N/A
- Fundamental
- Price
- CANF $1.03
- INDP $12.00
- Analyst Decision
- CANF Strong Buy
- INDP Strong Buy
- Analyst Count
- CANF 2
- INDP 2
- Target Price
- CANF $14.00
- INDP $238.00
- AVG Volume (30 Days)
- CANF 144.2K
- INDP 699.0K
- Earning Date
- CANF 08-29-2025
- INDP 08-11-2025
- Dividend Yield
- CANF N/A
- INDP N/A
- EPS Growth
- CANF N/A
- INDP N/A
- EPS
- CANF N/A
- INDP N/A
- Revenue
- CANF $674,000.00
- INDP N/A
- Revenue This Year
- CANF $461.72
- INDP N/A
- Revenue Next Year
- CANF N/A
- INDP N/A
- P/E Ratio
- CANF N/A
- INDP N/A
- Revenue Growth
- CANF N/A
- INDP N/A
- 52 Week Low
- CANF $0.98
- INDP $7.56
- 52 Week High
- CANF $4.69
- INDP $66.64
- Technical
- Relative Strength Index (RSI)
- CANF 43.30
- INDP 53.68
- Support Level
- CANF $1.00
- INDP $9.45
- Resistance Level
- CANF $1.09
- INDP $13.40
- Average True Range (ATR)
- CANF 0.03
- INDP 2.17
- MACD
- CANF 0.00
- INDP 0.20
- Stochastic Oscillator
- CANF 45.00
- INDP 29.39
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.